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Introduction: There is a need for continuous glucose monitoring in critically ill patients. The objective of this trial
was to determine the point accuracy and reliability of a device designed for continuous monitoring of interstitial
glucose levels in intensive care unit patients.
Methods: We evaluated point accuracy by comparing device readings with glucose measurements in arterial blood
by using blood gas analyzers. Analytical and clinical accuracy was expressed in Bland-Altman plots, glucose prediction
errors, and Clarke error grids. We used a linear mixed model to determine which factors affect the point accuracy. In
addition, we determined the reliability, including duration of device start-up and calibration, skips in data acquisition,
and premature disconnections of sensors.
Results: We included 50 patients in whom we used 105 sensors. Five patients from whom we could not collect the
predefined minimum number of four consecutive comparative blood draws were excluded from the point accuracy
analysis. Therefore, we had 929 comparative samples from 100 sensors in 45 patients (11 (7 to 28) samples per patient)
during 4,639 hours (46 (27 to 134) hours per patient and 46 (21 to 69) hours per sensor) for the accuracy analysis. Point
accuracy did not meet the International Organization for Standardization (ISO) 14971 standard for insulin dosing
accuracy but did improve with increasing numbers of calibrations and was better in patients who did not have a
history of diabetes. Out of 105 sensors, 60 were removed prematurely for a variety of reasons. The device start-up time
was 49 (43 to 58) minutes. The number of skips in data acquisition was low, resulting in availability of real-time data
during 95% (89% to 98%) of the connection time per sensor.
Conclusions: The point accuracy of a device designed for continuous real-time monitoring of interstitial glucose levels
was relatively low in critically ill patients. The device had few downtimes, but one third of the sensors were removed
prematurely because of unresolved sensor- or device-related problems.
Trial registration: Netherlands Trial Registry number: NTR3827. Registered 30 January 2013.Introduction
Handheld blood glucose meters or department-based
blood gas analyzers are currently the preferred methods
to measure blood glucose levels in intensive care unit
(ICU) patients [1,2]. These intermittent glucose-monitoring
techniques have variable accuracies [3] but foremost lack
useful trending because of the interval between consecutive* Correspondence: r.t.vanhooijdonk@amc.uva.nl
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article, unless otherwise stated.measurements. Continuous glucose monitoring (CGM)
is suggested to increase practicalities and safety of insu-
lin titration in ICU patients [1,4], in particular when
targeting normal or near-normal blood glucose levels
when hypoglycemic episodes can be expected [5-13].
Glucose oxidase technique-based interstitial CGM
devices have been used before in diabetic patients outside
the ICU setting [14]. It is uncertain, however, whether
interstitial CGM devices are point accurate in critically ill
patients [1]. An altered relationship between blood and
interstitial fluid glucose levels during critical illness couldCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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blood glucose level [15]. Several interstitial CGM sensor
systems originally designed for non-ICU patients have
been tested in the ICU setting in recent years [16-28].
Medtronic MiniMed (Medtronic Inc., Northridge, CA,
USA) developed the Sentrino Continuous Glucose Man-
agement System, an interstitial CGM device that was
especially designed for use in critically ill patients. This
device was improved from previous models by creating
the processor cable and pole-mounted monitor and by
four sensing elements designed to increase responsiveness
to glucose changes and to limit the influence from drug
interactions.
The aim of this study was to test its point accuracy
and reliability in a mixed medical-surgical ICU. We
hypothesized that the device would provide an accurate
reflection of the blood glucose level in ICU patients
treated according to a local guideline for blood glucose
control targeting blood glucose levels between 90 and
144 mg/dL. In addition, we determined its reliability,
including duration of the device start-up, the need for
calibration, skips in data acquisition, and number of and
reasons for premature disconnections.
Methods
Study design and informed consent
This was an investigator-initiated observational trial.
The Institutional Review Board of the Academic Medical
Center (Amsterdam, The Netherlands) approved the
study protocol (study ID: NL41498.018.12). Medtronic
MiniMed provided three devices for the duration of the
trial and the necessary sensors but had no influence on
study design or study reporting. Patients or next of kin
had to provide written informed consent before the start
of any study-related procedure.
Study population
Patients were recruited between October 2012 and
February 2014 in a 30-bed mixed medical-surgical ICU
of a large university hospital (Academic Medical Center).
Patients were eligible for inclusion if they were at least
18 years old and had an anticipated life expectancy of
more than 96 hours. Patients were excluded from
participation if they had a platelet count of less than
30 × 109/L, had participated in a trial testing an investi-
gational product or treatment within the past 30 days,
were pregnant, or had a suspected or diagnosed medical
condition which in the opinion of the investigators pre-
vented the patient from completing the study.
Glucose control
ICU nurses performed glucose control with insulin by
following a local guideline for blood glucose control tar-
geting a blood glucose level between 90 and 144 mg/dL[29]. Insulin titration adjustments were based on sliding
scales. The local guideline for blood glucose control
dictated nurses to perform blood glucose measurements
at least every 4 hours and more frequently if blood glu-
cose levels were out of range or were expected to change
rapidly. For details, see Additional file 1.
During the study, ICU nurses were not allowed to
change insulin infusion rate based on the readings by
the investigational device. However, they were allowed
to perform additional blood glucose measurements if the
device suggested rapid changes in the glucose level or
when there was a trend toward hypoglycemia.
The investigational device
The disposable glucose sensors of the device were glucose
oxidase-based; each sensor had two probes, and each
probe had two sensing elements. The individual measure-
ment results were combined and displayed on the device
monitor every minute. The signal was transmitted through
the processor cable to the monitor. It was a single-patient
single-use sensor, which could be used for up to 72 hours.
The processor cable was reusable.
The sensor was inserted into the subcutaneous tissue
by using two parallel introducer needles. The two needles
automatically retracted when the introducer hub was
pulled away from the sensor base; the sensor probes
remained in the subcutis. Each new sensor needed calibra-
tion by using blood glucose levels after insertion and
initialization and after 1 hour and 2 hours; thereafter,
repeated calibrations were performed every 8 hours.
Study procedures
Sensors were inserted into the subcutis of the thigh.
Successive sensors could be used for 72 hours, depending
on length of stay in the ICU, but never for longer than
30 days. Arterial blood glucose levels were measured by
using RapidLab 1265 blood gas analyzers (Siemens
Healthcare Diagnostics, The Hague, The Netherlands),
which were used for calibrations of the device. Not only
did ICU nurses provide the mandatory calibration blood
glucose levels, but also the routinely obtained blood
glucose levels (that is, blood glucose measurements which
were not requested by the device for calibrations but were
taken by the nurses as dictated by the local guideline for
blood glucose control) were entered into the device as
well. Therefore, these measurements were also used for
calibrations of the device. If the device displayed a mes-
sage requesting an additional non-routine calibration to
resolve a sensor performance issue (that is, a ‘Poor Sensor
Signal’ alert), the nurses were permitted to disregard
manufacturer recommendation and remove sensors rather
than enter the requested calibration.
Each day, the place of insertion was photographed and
inspected for redness, bruises, and swelling. In case the
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was painful. Every item could be scored as ‘none’, ‘minor’,
or ‘major’.Power calculation
We intended to enroll 50 patients to assess accuracy of
the CGM device. With 50 patients, we expected to have
at least 40,000 subcutaneous CGM device results and at
least 1,200 blood glucose level measurements with the
RapidLab 1265. Considering previous studies testing
point accuracy, we assumed we would have a sufficiently
high number of paired samples to enable evaluation of
the point accuracy of the device.Analysis plan
The glucose data collected with each new sensor were
downloaded from the device after use in a patient; the
arterial blood glucose levels were downloaded from the
patient data management system. The arterial blood
glucose levels in the patient data management system
were compared with the entries for calibrations into the
device. In case of an entry error, defined as a difference
between the arterial blood glucose level in the patient
data management system and the calibration entry of
more than 9 mg/dL, the correct blood glucose level was
used in the accuracy analysis. The subsequent pairs,
though, were excluded from the accuracy analysis since
these were influenced by the preceding entry.
For reporting point accuracy, we used analytical and
clinical accuracy measures: that is, Bland-Altman plot
with bias and limits of agreement (bias ± 1.96 × standard
deviation of the bias) [30], glucose prediction errors, and
Clarke error grid analyses [31]. According to Inter-
national Organization for Standardization (ISO) criteria,
95% of the paired measurements should be within the
glucose prediction error criteria; the consensus is that
95% of the values should be in zones A and 5% in zones
B of Clarke error grid analyses. Finally, we expressed the
linearity between the device glucose results and blood
glucose results by the Pearson correlation coefficient
and coefficient of determination, R2.
In a post hoc analysis, we also report point accuracy
according to the recently published consensus recom-
mendations [1]. In this round-table meeting of ICU
experts in blood glucose control, it was recommended
to always report the mean absolute relative difference
(MARD) when testing a CGM device, where MARD
values should be less than 14%; values of more than 18%
should be considered to represent poor accuracy [32].
We added the MARD as a post hoc analysis. Further-
more, we analyzed the point accuracy following the
recently published surveillance error grid [33]. For more
details, see Additional file 1.We also reported reasons for early disconnection,
defined as the removal of a sensor before 72 hours. For de-
tails, see Additional file 1. The time between calibrations
using an incorrect glucose value entry and the next calibra-
tion was extracted from the total connection time of the
device. Definitions of the metrics used to assess device
reliability, including those suggested by recent consensus
recommendations [1], are described in Additional file 1.
Statistical analysis
We reported data as mean (± standard deviation) or
median (interquartile range, or IQR) where appropriate.
To be considered for the statistical analysis, each patient
needed to have at least four comparative blood glucose
results for accuracy analysis. However, the excluded
patients remained included in the reliability analysis.
In a post hoc analysis, we used a linear mixed model to
determine which variables influence the accuracy of the
device. In addition, we stratified the accuracy results by
diabetic status. For a detailed description of this model,
see Additional file 1. Analyses were performed by using




We included 50 patients. In total, we used 105 sensors
(median of 1 (IQR 1 to 3) sensor per patient) with a total
connection time of 4,639 hours (median of 46 (IQR 27
to 134) hours per patient and median of 46 (IQR 22 to 69)
hours per sensor). Five patients from whom we could
not collect the minimum number of four consecutive
comparative blood draws were excluded from the point
accuracy analysis. A CONSORT (Consolidated Standards
of Reporting Trials) diagram is provided in Figure 1.
Patient characteristics and metrics of glucose control are
shown in Tables 1 and 2.
We could not inspect the insertion site of three sensors.
Major bruises were observed in 3 out of 102 inspected
insertion sensor sites; 10 minor bruises were seen. Major
redness of the skin was observed in 7 out of 102 insertion
sensor sites, and minor redness in 6 out of 102 insertion
sites. Swelling of the skin was never seen, and none of the
conscious patients mentioned pain at the sensor insertion
site.
Point accuracy
We collected 929 comparative samples (11 (IQR 7 to 28)
samples per patient). Bland-Altman plot, glucose predic-
tion error grid, and Clarke error grid are presented in
Figure 2. The surveillance error grid is presented in
Figure 3. The Pearson correlation coefficient was 0.81;
the R2 was 0.65. The MARD was 14.8%.
Patients screened 
N = 790 
Excluded: 
- discharge < 24 hours N = 531 
- No Informed Consent N = 61 
- life expectancy < 96 hours N = 42  
- missed N = 40 
- platelet count < 30 N = 21 
- doctor exclusion N = 16 
- not willing to participate N = 15 
- in other trial N = 5 
- pregnant N = 3 
- no monitor available N = 2 
- age < 18 years N = 2 
- readmission already included N = 20 
Included patients 
N = 50 
Included in the point accuracy analysis 
N = 45 
Comparative samples < 4 N = 5 
Figure 1 CONSORT (Consolidated Standards of Reporting Trials)
diagram of the study.
Table 1 Patient characteristics




the point accuracy analysis
Age in years, median (IQR) 65 (56-72) 65 (55-72)
Male gender, number (%) 25 (50%) 24 (53%)
Race, number (%)
Caucasian 45 (90%) 40 (89%)
Black 4 (8%) 4 (9%)
Asian 1 (2%) 1 (2%)
BMI in kg/m2,
median (IQR)
24.7 (22.4-27.6) 24.4 (22.2-27.3)
Admission diagnosis,
number (%)
Medical 31 (62%) 26 (58%)
Emergency surgery 11 (22%) 11 (24%)
Planned surgery 8 (16%) 8 (18%)
Planned admission,
number (%)
10 (20%) 9 (20%)
History of diabetes,
number (%)
No diabetes 39 (78%) 34 (76%)
Diabetes, unknown
treatment
2 (4%) 2 (4%)
Diabetes treated
with insulin
4 (8%) 4 (9%)
Diabetes treated
with oral agents
5 (10%) 5 (12%)
APACHE II score,
median (IQR)
23 (17-26) 22 (17-25)
SAPS II, median (IQR) 46 (39-55) 46 (40-55)
ICU LOS in days,
median (IQR)
9 (4-16) 11 (5-16)
Hospital LOS in
days, median (IQR)
19 (10-35) 19 (11-35)
ICU mortality, number (%) 11 (22%) 10 (22%)
Hospital mortality, 15 (30%) 14 (31%)
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12.5% of the arterial blood glucose results (or within
10 mg/dL for results of less than 99 mg/dL), and 75%
were within 20% of the arterial blood glucose results.
In the linear mixed model, only history of diabetes
(P = 0.02) and number of calibrations per sensor (P = 0.04)
affected the absolute difference between blood glucose
and device result. Per each new calibration, the absolute
difference decreased by 1.4% (standard error of 0.006%),
meaning that the sensor performance increased. The
effect of a history of diabetes was larger since an increase
by 34.3% (standard error of 13.0%) in the absolute differ-
ence was found when comparing patients with a history of
diabetes and patients without diabetes. In addition, we
stratified the accuracy results by diabetic status; results are
shown in Additional file 1: Figure S1 and Table S2. For
detailed results of the multivariate random intercept
model, see Additional file 1.number (%)
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass
index; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay;
SAPS II, Simplified Acute Physiology Score II.Reliability of the continuous glucose-monitoring device
Start-up time after placing a new sensor was 49 (IQR 43
to 58) minutes. The number of skips in data acquisition
was low, resulting in availability of real-time data during
95% (IQR 89% to 98%) of the connection time per sensor.
Table 3 summarizes reliability metrics of the investiga-
tional device.
Out of 105 sensors, 60 were removed before 72 hours;
the reasons for removal and the connection times of
sensors are shown in Table 4. Out of 105 sensors, 42
were removed before 72 hours after insertion for reasons
other than ICU discharge or death, and 36 sensors were
removed because of an unresolved ‘Poor Sensor Signal’
alert or a device error (19 with no attempt to resolve).Discussion
We determined the point accuracy and reliability of a
device specifically designed for continuous real-time
monitoring of interstitial glucose levels in critically ill
patients. The analytic point accuracy of the device was
low in a typical cohort of patients from a mixed medical-
surgical ICU, according to ISO criteria and consensus
recommendations. The clinical point accuracy was low
according to Clarke error grid analysis but better ac-
cording to surveillance error grid analysis. The device
had few downtimes, but one third of the sensors were
Table 2 Measures of blood glucose control in patients
included in point accuracy analysis
Number of measurements 929
Mean blood glucose level per patient
in mg/dL, median (IQR)
132 (125-148)
Standard deviation of blood glucose
level per patient in mg/dL, median (IQR)
24 (16-33)
Number of measurements per patient, median, (IQR) 11 (7-29)
Severe hypoglycemia ≤40 mg/dL in measurements,
number (%)
3 (0.3%)
Severe hypoglycemia ≤40 mg/dL in patients, number (%) 2 (4.4%)
Mild hypoglycemia 41-70 mg/dL in measurements,
number (%)
15 (1.6%)
Mild hypoglycemia 41-70 mg/dL in patients, number (%) 7 (15.6%)
Mild hyperglycemia 150 -179 mg/dL in measurements,
number (%)
163 (17.5%)
Mild hyperglycemia 150-179 mg/dL in patients,
number (%)
35 (77.8%)
Severe hyperglycemia >180 mg/dL in measurements,
number (%)
111 (11.9%)
Severe hyperglycemia >180 mg/dL in patients,
number (%)
19 (42.2%)
Data consider all paired measurements, and result of blood gas analyzer is
shown. IQR, interquartile range.
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related problems.
The present findings are in line with results from a previ-
ous trial testing the same device in cardiac surgery patients
[34]. In that study, the mean absolute relative differenceFigure 2 Bland-Altman plot with bias and limits of agreement (bias ±
and Clarke error grid analyses.was 12.2% with 95% real-time data. Similar results come
from studies testing other devices for interstitial glucose
monitoring that were originally designed for use in non-
critically ill patients. Those studies were performed in
cardiac surgery patients [21,24,35], surgery patients [26],
patients with neurologic emergencies [27], and non-
surgical patients [16,22,25], and only two reported more
favorable accuracy results [21,22]. Taken together, these
data suggest that point accuracy of interstitial glucose mon-
itoring cannot replace blood glucose level measurements.
In contrast to our findings, a previous publication by
Brunner et al. [18] suggests a better point accuracy of
another interstitial CGM device in critically ill patients.
This report combined data of two separate trials in
medical ICU patients [19,36]. The tested device in that
study was from the same manufacturer but was not
specifically designed for use in critically ill patients. In
addition, the sensor was used for up to 72 hours and
never replaced. One important difference with the present
study was that the sensors were placed exclusively under
the skin of the abdomen in patients included in these two
trials. In most other trials, sensors were inserted under the
skin of the abdomen [16,18,22,24,26,28], thigh [25,26], or
shoulder [21]. Reported point accuracies do not suggest
superiority of one of these sites. Certainly, there could be
other unknown and unreported factors that could have
resulted in the differences in performance.
We performed a mixed linear model to determine
which factors could have influenced the point accuracy
of the tested sensor. Rank order of measurement and1.96 × standard deviation of the bias), glucose prediction errors,
Figure 3 Surveillance error grid with risk scores.
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The finding that rank order of measurement improved
sensor performance is not new [18] and certainly is not
surprising: more calibrations may always increase accur-
acy of a sensor. A history of diabetes was the mostimportant variable influencing point accuracy and dete-
riorated sensor performance by 34%. As yet, this effect
remains unexplained. It could be that microcirculation
alteration in patients with diabetes affects interstitial glu-
cose level. However, in previous studies with interstitial
Table 3 Device reliability
Per patient Per sensor
Total number of sensors used - 105
Number of sensors used, median (IQR) 1 (1-3) -
Total connection time in hours, median (IQR) 46.2 (26.8-134.2) 45.8 (21.1-69.1)
Start-up time in minutes, median (IQR) Median 49 (44-58) 49 (43-57.9)
Initialization time in minutes, median (IQR) Median 34 (34-34.5) 34 (34,35)
Real-time data in hours 42.3 (23.1-130.3) 41.4 (20.6-64.0)
Percentage of real-time data, median (IQR) 94.1 (88.9-97.1) 94.6 (88.7-97.9)
Time of skips in data acquisition in hours, median (IQR) 4.3 (1.2-9.1) 2.6 (0.6-5.4)
Time of skips in data acquisition in hours caused by poor sensor signal, median (IQR) 0 (0-1.0) 0 (0-0.2)
Time of skips in data acquisition in minutes caused by other reasons, median (IQR) 3.3 (0.9-8.4) 2.0 (0.4-3.7)
Percentage of time of skips in data acquisition, median (IQR) 5.9 (2.9-11.1) 5.4 (2.1-11.3)
Percentage of time of skips in data acquisition in caused by poor sensor signal, median (IQR) 0 (0-0.7) 0 (0-0.3)
Percentage of time of skips in data acquisition caused by other reasons, median (IQR) 4.2 (2.3-8.0) 3.8 (1.5-8.0)
Number of calibrations, median (IQR) 14 (9-34) 12 (7-16)
Number of mandated calibrations, median (IQR) 8 (4-20) 6 (4-8)
IQR, interquartile range.
van Hooijdonk et al. Critical Care  (2015) 19:34 Page 7 of 10devices, diabetes was not found to be significantly asso-
ciated with poor sensor accuracy in critically ill and
cardiac surgery patients [16,18,28]. Moreover, in a
recent study in cardiac surgery patients, an impaired
microcirculation did not affect accuracy of two interstitialTable 4 Sensors removed less than 72 hours
Total number of sensors used 1
Total number of sensors removed <72 hours 6
N
Patient-related factors
Discharge <72 hours after insertion
Death 72 hours after insertion
Sensor- or device-related factors
Accidental removal of sensor
Poor sensor signal (19 had no attempt to resolve)
Device error
Duration of sensors in place in hours, median (IQR)
All sensors 4
Sensor that were removed <72 hours 2
Sensors that were removed <72 hours because of patient-related factors 2
Discharge <72 hours after insertion 2
Death 72 hours after insertion 3
Sensors that were removed <72 hours because of patient-related factors 1
Accidental removal of sensor 2
Poor sensor signal 1
Device error 8
IQR, interquartile range.glucose sensors from two different manufacturers [28].
The difference found between patients with and without
diabetes might also be related to glucose variability.
Patients with diabetes will have more glucose variability
compared with patients without diabetes. Thereby, when05
0
umber of sensors Percentage of sensors
removed <72 hours
Percentage of total
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be found when variability differences are compared.
It should be stressed that we compared interstitial glu-
cose measurements with glucose levels in arterial blood
samples, which are far from comparable. Indeed, the
interstitial glucose level is dependent on several factors
other than the blood glucose level, such as the speed of
glucose diffusion from blood to interstitial spaces, as well
as the rate of glucose uptake by subcutaneous cells [37].
Importantly, these factors are not constant, particularly in
critically ill patients. Furthermore, there is a time lag
between interstitial glucose and blood glucose measure-
ment [37]. Studies suggested that the interstitial glucose
level decreases before the blood glucose decreases [37,38],
although this was not confirmed in other studies [39]. It is
probably very difficult, if not impossible, to correct for
factors causing a difference between interstitial and
arterial blood glucose levels. Moreover, it is unknown
whether differences between arterial and interstitial
glucose levels are physiological.
Nevertheless, subcutaneous glucose monitoring could
have advantages. One potential advantage is that con-
tinuous monitoring of interstitial glucose levels enables
detection of trends in the blood glucose level [32]. This
could allow earlier responses to a rise or a decline of
the blood glucose level. In both cases, knowledge of the
direction of the trend may be more valuable than the
exact blood glucose level.
It is clear that the tested device can never replace
blood glucose measurements. First, initial calibrations
are always necessary, as are calibrations every 8 hours
thereafter. As nurses were allowed to perform additional
blood glucose measurements and as we asked them to
insert the values into the investigational device monitor
where they were used for additional calibrations, the
number of calibrations in this study was higher than
mandated. In fact, this could have improved the accuracy
of the investigational device: it is possible that with fewer
calibrations, point accuracy becomes worse.
Our trial has several strengths and weaknesses. Strengths
include the fact that we were able to use the sensors for
several days in the participating patients. Moreover, we
used accurate blood gas analyzer measurements for com-
parisons as well as for the calibrations. Furthermore, we
were able to test the device in a typical mixed medical-
surgical ICU. Weaknesses include the small sample size
and the single-center design of the trial. Furthermore, we
did not collect as many samples as we expected. A more
important limitation of our trial, though, is that the vast
majority of blood glucose levels were in a narrow range,
preventing us from drawing firm conclusions regarding ac-
curacy in the hypoglycemic range. Although the ICU
nurses were not allowed to change insulin infusion rates,
they could have anticipated hypoglycemia by performingnew blood glucose measurements earlier than dictated by
the local guideline for blood glucose control, allowing them
to respond earlier to, for example, hypoglycemia. Still, some
hypoglycemic events occurred, probably because not all
nurses were paying attention to the readings of the investi-
gational device. In addition, nurses could have noted that
its point accuracy was not always good, so they could have
mistrusted the device readings. Finally, we cannot exclude
the possibility that hypoglycemia can occur even with the
use of CGM. The latter possibility will be the subject of a
planned trial. An accuracy analysis limitation was that the
assessment focused on percentage difference comparisons
between the continuous sensor and discrete reference
points, evaluated by standards meant for discrete measure-
ments for dosing. Another important limitation is that
trend accuracy was not evaluated. Trending is the most
interesting endpoint but mandates very short intervals (that
is, a short as 15 minutes) between blood glucose reference
measurements [32,40]. Trend accuracy should and will be
evaluated in future studies.
Notably, length of stay in the ICU and sensor connection
time were far from similar. This was caused by the fact that
sensors could not be used before informed consent was
obtained. Thus, we may have missed an important phase
of glucose control (that is, the first day or days of stay in
the ICU). In addition, because of sensor- or device-related
factors, one third of the sensors were removed before
sensor life ended. This is an important problem for the
reliability of the device. However, nurses did not always
attempt to solve sensor- or device-related problems that
could have been solved. During conduct of the trial, they
were always allowed to remove the sensor because of ‘Poor
Sensor Signal’ alerts or recurrent alarms. With increasing
device-specific experience, it could be that there are fewer
early removals.
Conclusions
The point accuracy of a device designed for continuous
real-time monitoring of the interstitial glucose level did
not meet the ISO15197 standard or the recent consensus
guidance for discrete glucose measurement for dosing
when used on critically on critically ill patients admitted
to a mixed medical-surgical ICU. Although this device is
not a replacement for current blood gas analyzer measure-
ments, a real-time system may be used for trend guidance
on timely reference measurement for insulin adjustment.
The device had few downtimes, but one third of the sen-
sors were removed prematurely because of unresolved
sensor- or device-related problems.
Key messages
 An interstitial glucose sensor system in critically ill
patients cannot replace blood glucose level
van Hooijdonk et al. Critical Care  (2015) 19:34 Page 9 of 10measurements but may provide important trend
information for glucose management.
 Sensors are frequently removed prematurely for a
variety of reasons.Additional file
Additional file 1: Extended method section describing the local
guideline for glucose control, methods to calculate point accuracy,
definitions of metrics for device reliability. Post hoc analysis about
factors that affect point accuracy including Table S1 with results from
the linear mixed model, Table S2 with accuracy metrics stratified by
diabetic status, and Figure S1 with Bland-Altman plot with bias and
limits of agreement (bias ± 1.96 standard deviation of the bias), glucose
prediction errors, and Clarke error grid analyses stratified by diabetic status.Abbreviations
CGM: continuous glucose monitoring; ICU: intensive care unit;
IQR: interquartile range; ISO: International Organization for Standardization;
MARD: mean absolute relative difference.
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